BRL42715

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 466140

CAS#: 102209-75-6 (sodium)

Description: BRL42715 is an active-site-directed inactivator of bacterial beta-lactamases.

Chemical Structure

img
BRL42715
CAS# 102209-75-6 (sodium)
Instruction

Theoretical Analysis

MedKoo Cat#: 466140
Name: BRL42715
CAS#: 102209-75-6 (sodium)
Chemical Formula: C10H7N4NaO3S
Exact Mass: 286.01
Molecular Weight: 286.241
Elemental Analysis: C, 41.96; H, 2.47; N, 19.57; Na, 8.03; O, 16.77; S, 11.20

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: BRL42715; BRL 42715; BRL-42715;

IUPAC/Chemical Name: sodium (R,E)-6-((1-methyl-1H-1,2,3-triazol-4-yl)methylene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

InChi Key: OMJBLZMKGVWHQP-MPXWGJQKSA-M

InChi Code: InChI=1S/C10H8N4O3S.Na/c1-13-3-5(11-12-13)2-6-8(15)14-7(10(16)17)4-18-9(6)14;/h2-4,9H,1H3,(H,16,17);/q;+1/p-1/b6-2+;/t9-;/m1./s1

SMILES Code: O=C(C(N1C/2=O)=CS[C@]1([H])C2=C\C3=CN(C)N=N3)[O-].[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 286.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Jones RN, Deshpande LM, Bell JM, Turnidge JD, Kohno S, Hirakata Y, Ono Y, Miyazawa Y, Kawakama S, Inoue M, Hirata Y, Toleman MA. Evaluation of the contemporary occurrence rates of metallo-beta-lactamases in multidrug-resistant Gram-negative bacilli in Japan: report from the SENTRY Antimicrobial Surveillance Program (1998-2002). Diagn Microbiol Infect Dis. 2004 Aug;49(4):289-94. doi: 10.1016/j.diagmicrobio.2004.04.007. PMID: 15313535.

2: Yamaguchi K, Mathai D, Biedenbach DJ, Lewis MT, Gales AC, Jones RN. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis. 1999 Jun;34(2):123-34. doi: 10.1016/s0732-8893(99)00019-x. PMID: 10354863.

3: Li XZ, Zhang L, Srikumar R, Poole K. Beta-lactamase inhibitors are substrates for the multidrug efflux pumps of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1998 Feb;42(2):399-403. doi: 10.1128/AAC.42.2.399. PMID: 9527793; PMCID: PMC105421.

4: Phillips OA, Czajkowski DP, Spevak P, Singh MP, Hanehara-Kunugita C, Hyodo A, Micetich RG, Maiti SN. SYN-1012: a new beta-lactamase inhibitor of penem skeleton. J Antibiot (Tokyo). 1997 Apr;50(4):350-6. doi: 10.7164/antibiotics.50.350. PMID: 9186563.

5: Kunugita C, Higashitani F, Hyodo A, Unemi N, Inoue M. Characterization of a new plasmid-mediated extended-spectrum beta-lactamase from Serratia marcescens. J Antibiot (Tokyo). 1995 Dec;48(12):1453-9. doi: 10.7164/antibiotics.48.1453. PMID: 8557603.

6: Satake S, Nakae T. Outer membrane permeability of beta-lactamase inhibitors in Pseudomonas aeruginosa. FEMS Microbiol Lett. 1995 Jun 15;129(2-3):251-4. doi: 10.1111/j.1574-6968.1995.tb07588.x. PMID: 7607408.

7: Galleni M, Franceschini N, Quinting B, Fattorini L, Orefici G, Oratore A, Frère JM, Amicosante G. Use of the chromosomal class A beta-lactamase of Mycobacterium fortuitum D316 to study potentially poor substrates and inhibitory beta-lactam compounds. Antimicrob Agents Chemother. 1994 Jul;38(7):1608-14. doi: 10.1128/AAC.38.7.1608. PMID: 7979294; PMCID: PMC284600.

8: Muratani T, Yokota E, Nakane T, Inoue E, Mitsuhashi S. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam. J Antimicrob Chemother. 1993 Sep;32(3):421-9. doi: 10.1093/jac/32.3.421. PMID: 8262864.

9: Zhou XY, Kitzis MD, Gutmann L. Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1993 Jun;37(6):1387-9. doi: 10.1128/AAC.37.6.1387. PMID: 8328794; PMCID: PMC187975.

10: Ephtimios IE, Barrett MS, Wenzel RP, Jones RN. In-vitro antimicrobial activity of the penem BRL-42715, alone and in combination with ampicillin, against respiratory tract pathogens. J Antimicrob Chemother. 1992 May;29(5):599-600. doi: 10.1093/jac/29.5.599. PMID: 1624400.

11: Livermore DM, Seetulsingh P. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin . J Antimicrob Chemother. 1991 Jun;27(6):761-7. doi: 10.1093/jac/27.6.761. PMID: 1669013.

12: Jackson D. Evolution of beta-lactamase inhibitors. Pharmacotherapy. 1991;11(2 ( Pt 2)):37S-39S. PMID: 2041830.